EUVIMEDEUVIMED entdecken
Crossref

The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study

Georgia Kourlaba, Georgios Koutsis, Nikolaos Fakas, Vana Tsimourtou, Georgios Karachalios, Christos Bakirtzis, Nikolaos Grigoriadis

Expert Review of Pharmacoeconomics & Outcomes Research · 2026

DOI: 10.1080/14737167.2025.2603955 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von Georgia Kourlaba und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Faculty of Health Science, University of Peloponnese, Tripoli, Greece. Hauptthemen laut MEDLINE: Dimethyl Fumarate, Multiple Sclerosis, Relapsing-Remitting, Cost of Illness, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Genesis Pharma S.A.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The review of healthcare costs in multiple sclerosis (MS) has been of increased interest. In this study, we aimed to estimate the economic burden of MS patients, treated with dimethyl fumarate (DMF) in Greece. RESEARCH DESIGN AND METHODS: Four hundred and fifty-six participants were followed every 6 months after DMF initiation. Healthcare resource utilization, out-of-pocket expenses, and productivity loss data were recorded. Treatment cost and effectiveness of DMF were compared with those of previous treatments. RESULTS: From a societal perspective, the total mean biennial burden was 13,113 € per patient, mainly attributed to direct healthcare costs (10,818 €, with medication accounting for almost 96%). From the payer perspective, the cost per patient was estimated at 10,462 €. The main driver of indirect cost was early retirement (87.8%). The treatment cost in the 2 years before the study was ~25% higher than the biennial DMF cost. A total of 43.9% of the patients experienced adverse events, mostly mild/moderate. CONCLUSIONS: DMF displayed a societal cost mainly driven by medication, disease severity, disease duration and patients' age. There was evidence of beneficial effects on disease activity and quality of life with no new safety signals emerging. TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (ID: NCT03101735).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dimethyl FumarateMultiple Sclerosis, Relapsing-RemittingCost of IllnessImmunosuppressive AgentsHealth Care CostsHumansGreeceFemaleMaleAdultMiddle AgedTreatment OutcomeCost-Benefit AnalysisSeverity of Illness IndexPatient Acceptance of Health CareTime FactorsFollow-Up StudiesHealth ExpendituresAge FactorsYoung Adult

Stichwörter der Autor:innen

Multiple sclerosisadherence to treatmentdimethyl fumaratehealthcare resource utilizationquality of life

Substanzen

Dimethyl FumarateImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nursing, Faculty of Health Science, University of Peloponnese, Tripoli, Greece.
  • Neurogenetics Unit, First Department of Neurology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Neurology, 401 General Military Hospital of Athens, Athens, Greece.
  • Department of Neurology, University Hospital of Larissa, Larissa, Greece.
  • Department of Medical Affairs, Genesis Pharma S.A., Athens, Greece.
  • Multiple Sclerosis Center, Second Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Förderung

  • Genesis Pharma S.A

Zitieren

APA

Kourlaba, G., Koutsis, G., Fakas, N., Tsimourtou, V., Karachalios, G., Bakirtzis, C., & Grigoriadis, N. (2026). The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2603955

Vancouver

Kourlaba G, Koutsis G, Fakas N, Tsimourtou V, Karachalios G, Bakirtzis C, et al. The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2025.2603955

BibTeX
@article{Kourlaba2026,
  author = {Kourlaba, Georgia and Koutsis, Georgios and Fakas, Nikolaos and Tsimourtou, Vana and Karachalios, Georgios and Bakirtzis, Christos and Grigoriadis, Nikolaos},
  title = {The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  doi = {10.1080/14737167.2025.2603955}
}
Kostenlos starten →